Deferred State and Local Income Tax Expense (Benefit) of ZyVersa Therapeutics, Inc. from 12 Dec 2022 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
ZyVersa Therapeutics, Inc. annual and quarterly Deferred State and Local Income Tax Expense (Benefit) in USD history and change rate from 12 Dec 2022 to 31 Dec 2024.
  • ZyVersa Therapeutics, Inc. Deferred State and Local Income Tax Expense (Benefit) for the quarter ending 31 Dec 2022 was $34,844.
  • ZyVersa Therapeutics, Inc. annual Deferred State and Local Income Tax Expense (Benefit) for 2024 was $164,376, a 96% increase from 2023.
  • ZyVersa Therapeutics, Inc. annual Deferred State and Local Income Tax Expense (Benefit) for 2023 was $4,468,170, a 826% decline from 2022.
Source SEC data
View on sec.gov
Deferred State and Local Income Tax Expense (Benefit), Annual (USD)
Deferred State and Local Income Tax Expense (Benefit), YoY Annual Change (%)
Deferred State and Local Income Tax Expense (Benefit), Quarterly (USD)

ZyVersa Therapeutics, Inc. Annual Deferred State and Local Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $164,376 +$4,303,794 +96% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $4,468,170 -$3,985,887 -826% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $482,283 01 Jan 2022 12 Dec 2022 10-K 25 Mar 2024 2023 FY

ZyVersa Therapeutics, Inc. Quarterly Deferred State and Local Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2022 $34,844 31 Dec 2022 10-K 25 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.